March 25, 2011
1 min read
Save

Rivaroxaban may offer safe, effective treatment of venous thrombosis

Bauersachs R. N Engl J Med. 2010;363:2499-2510.

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Researchers have reported that rivaroxaban may provide a single-drug approach to the short-term and continued treatment of venous thrombosis and may improve the benefit-to-risk profile of anticoagulation.

The Acute DVT trial, one of three randomized trials of the EINSTEIN program, was an open-label, event-driven, noninferiority study comparing oral rivaroxaban (Xarelto, Bayer; n=1,731) with enoxaparin plus a vitamin K antagonist (n=1,718) for 3, 6 or 12 months in patients with acute, symptomatic deep vein thrombosis. Researchers also carried out a continued treatment trial, which was a randomized, double blind, event-driven superiority study comparing rivaroxaban alone (n=602) with placebo (n=594) for an additional 6 or 12 months in patients who had completed 6 to 12 months of treatment for venous thromboembolism.

Results from the Acute DVT trial indicated noninferiority efficacy for rivaroxaban regarding the primary efficacy outcome of recurrent VTE (2.1% vs. 3%; HR=0.68; 95% CI, 0.44-1.04). The principal safety outcome of major bleeding or clinically relevant nonmajor bleeding occurred in 8.1% of the patients in both groups.

According to data from the continued-treatment trial, rivaroxaban had a superior event rate of recurrent VTE compared with placebo (1.3% vs. 7.1%; HR=0.18; 95% CI, 0.09-0.39).

This led researchers to conclude that “oral rivaroxaban, at a dose of 15 mg twice daily for the first 3 weeks, followed by 20 mg once daily thereafter, without the need for laboratory monitoring, may provide an effective, safe, single-drug approach to the initial and continued treatment of venous thrombosis.”

Twitter Follow HemOncToday.com on Twitter.